-
Je něco špatně v tomto záznamu ?
Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents
J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh, V. Klimešová,
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- antituberkulotika chemie farmakologie MeSH
- druhová specificita MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- mnohočetná léková rezistence účinky léků MeSH
- molekulární struktura MeSH
- Mycobacterium tuberculosis účinky léků MeSH
- tetrazoly chemie farmakologie MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
In this study, we described the structure-activity relationships of substituted 3,5-dinitrophenyl tetrazoles as potent antitubercular agents. These simple and readily accessible compounds possessed high in vitro antimycobacterial activities against Mycobacterium tuberculosis, including clinically isolated multidrug (MDR) and extensively drug-resistant (XDR) strains, with submicromolar minimum inhibitory concentrations (MICs). The most promising compounds showed low in vitro cytotoxicity and negligible antibacterial and antifungal activities, highlighting their highly selective antimycobacterial effects. 2-Substituted 5-(3,5-dinitrophenyl)-2H-tetrazole regioisomers, which are the dominant products of 5-(3,5-dinitrophenyl)-1H-tetrazole alkylation, showed better properties with respect to antimycobacterial activity and cytotoxicity than their 1-substituted counterparts. The 2-substituent of 5-(3,5-dinitrophenyl)-2H-tetrazole can be easily modified and can thus be used for the structure optimization of these promising antitubercular agents. The introduction of a tetrazole-5-thioalkyl moiety at position 2 of the tetrazole further increased the antimycobacterial activity. These compounds showed outstanding in vitro activity against M. tuberculosis (MIC values as low as 0.03 μM) and high activity against non-tuberculous mycobacterial strains.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17013257
- 003
- CZ-PrNML
- 005
- 20170418110728.0
- 007
- ta
- 008
- 170413s2017 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2017.02.058 $2 doi
- 035 __
- $a (PubMed)28279848
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Němeček, Jan $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 245 10
- $a Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents / $c J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh, V. Klimešová,
- 520 9_
- $a In this study, we described the structure-activity relationships of substituted 3,5-dinitrophenyl tetrazoles as potent antitubercular agents. These simple and readily accessible compounds possessed high in vitro antimycobacterial activities against Mycobacterium tuberculosis, including clinically isolated multidrug (MDR) and extensively drug-resistant (XDR) strains, with submicromolar minimum inhibitory concentrations (MICs). The most promising compounds showed low in vitro cytotoxicity and negligible antibacterial and antifungal activities, highlighting their highly selective antimycobacterial effects. 2-Substituted 5-(3,5-dinitrophenyl)-2H-tetrazole regioisomers, which are the dominant products of 5-(3,5-dinitrophenyl)-1H-tetrazole alkylation, showed better properties with respect to antimycobacterial activity and cytotoxicity than their 1-substituted counterparts. The 2-substituent of 5-(3,5-dinitrophenyl)-2H-tetrazole can be easily modified and can thus be used for the structure optimization of these promising antitubercular agents. The introduction of a tetrazole-5-thioalkyl moiety at position 2 of the tetrazole further increased the antimycobacterial activity. These compounds showed outstanding in vitro activity against M. tuberculosis (MIC values as low as 0.03 μM) and high activity against non-tuberculous mycobacterial strains.
- 650 _2
- $a antituberkulotika $x chemie $x farmakologie $7 D000995
- 650 _2
- $a mnohočetná léková rezistence $x účinky léků $7 D018432
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a Mycobacterium tuberculosis $x účinky léků $7 D009169
- 650 _2
- $a druhová specificita $7 D013045
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a tetrazoly $x chemie $x farmakologie $7 D013777
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sychra, Pavel $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Macháček, Miloslav $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Benková, Markéta $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Karabanovich, Galina $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Konečná, Klára $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Kavková, Věra $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Stolaříková, Jiřina $u Regional Institute of Public Health, Department of Bacteriology and Mycology, Partyzánské náměstí 7, 70200, Ostrava, Czech Republic.
- 700 1_
- $a Hrabálek, Alexandr $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Vávrová, Kateřina $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Soukup, Ondřej $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Roh, Jaroslav $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: jaroslav.roh@faf.cuni.cz.
- 700 1_
- $a Klimešová, Věra $u Charles University, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 130, č. - (2017), s. 419-432
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28279848 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170418111036 $b ABA008
- 999 __
- $a ok $b bmc $g 1199722 $s 974035
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 130 $c - $d 419-432 $e 20170228 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20170413